deprexis

News

Orexo exits depression DTx alliance with GAIA

Four years after buying US rights to GAIA's digital therapeutic to help people with depression, Swedish drugmaker Orexo has terminated the deal.

News

Personalising digital mental health treatment

Orexo launches digital therapies for depression, alcohol mis...

Sweden’s Orexo has launched two digital therapies in the US earlier than expected, following changes to US regulations that allow early access during the COVID-19 crisis.

News

Merck rare tumour drug Ezmekly backed for NHS use

Merck's drug for tumours associated with rare disease neurofibromatosis type 1, Ezmekly, has been cleared for NHS use in children as young as two.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks